Advertisement

Topics

Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. Company Profile

03:20 EDT 24th June 2018 | BioPortfolio


News Articles [1968 Associated News Articles listed on BioPortfolio]

FDA accepts sBLA of Seattle Genetics’ ADCETRIS for Hodgkin lymphoma

The US Food and Drug Administration (FDA) has accepted filing of a supplemental biologics licence application (sBLA) by Seattle Genetics...Read More... The post FDA accepts sBLA of Seattle Genetics’...

PharmaMar lizensiert vollsynthetisch aus Meeressubstanzen gewonnene Payloads für Wirkstoff-Konjugate an Seattle Genetics

Madrid (ots/PRNewswire) - PharmaMar (MCE: PHM) hat heute die Unterzeichnung einer exklusiven Lizenzvereinbarung mit Seattle Genetics Inc. (SGEN: NASDAQ GS) bekanntgegeben, nach der Seattle Genetics...

Seattle Genetics to Acquire Cascadian Therapeutics for $614 Million, Adding Late-Stage Breast Cancer Program

att BOTHELL, Wash. & SEATTLE–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the signing of a definitive merger agr...

Seattle Genetics Acquires Cascadian Therapeutics, Continuing a Strong ...

On January 31, two Seattle biotech companies, Seattle Genetics and Cascadian Therapeutics, announced a merger agreement under which Seattle Genetics will acquire Cascadian Therapeutics for $614 millio...

Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma

In a closely watched result, Adcentris, a cancer drug sold by the biotech firm Seattle Genetics and the Japanese drug giant Takeda, outperformed traditional chemotherapy in front-line Hodgkin lymphoma...

Seattle Genetics To Acquire Cascadian Therapeutics

NewsThe acquisition will enhance Seattle Genetics’ portfolio of solid tumor programs with potential rapid registration pathways and provides global rights to a pivotal Phase 2 program in development...

Unum gets $5mm investment from Seattle Genetics

Concurrent with closing its initial public offering, Unum Therapeutics Inc. sold partner Seattle Genetics Inc. 416,666 common shares at the IPO price of $12 each, for proceeds of $5mm. The companies t...

Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a....

PubMed Articles [1052 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

Measurement of three-dimensional wavefronts using the Ichikawa-Lohmann-Takeda solution to the irradiance transport equation.

In this paper, we use the irradiance transport equation and the Fourier transform-based experimental solution given by Ichikawa-Lohmann-Takeda. We analyze experimental factors such as the digital filt...

Validation of the Seattle angina questionnaire in women with ischemic heart disease.

Although the Seattle Angina Questionnaire (SAQ) has been widely used to assess disease-specific health status in patients with ischemic heart disease, it was originally developed in a predominantly ma...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Donated chemical probes for open science.

Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality ...

Clinical Trials [712 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

Impact of Non-Commercialism Policy in Seattle Schools

This pilot study on the impact of a non-commercialism policy in Seattle schools will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on a...

Genetics Education: Preparing Physicians for the Future

This study examines the best way to teach genetics to family medicine residents. First year family medicine residents at the University of Toronto will be taught basic clinical genetics as...

Impact of Non-Commercialism Policy in Seattle Schools

This is a 3-year pilot study funded by National Institute of Health will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on and adopted b...

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

Companies [3226 Associated Companies listed on BioPortfolio]

Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the larges...

Takeda San Francisco, Inc.

Takeda San Francisco, Inc. (TSF), established in November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellence and Antib...

Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc.

Envoy Therapeutics Inc. and Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global lea...

More Information about "Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc." on BioPortfolio

We have published hundreds of Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. news stories on BioPortfolio along with dozens of Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. Clinical Trials and PubMed Articles about Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. Companies in our database. You can also find out about relevant Takeda Pharmaceutical Company Limited & Seattle Genetics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record